Contraceptive use in acne

Clinics in Dermatology

Volumn 32, Issue 4, 2014, Pages 502-515

  Lam, Charlene ^a   Zaenglein, Andrea L ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; ANDROSTENEDIONE; CANRENOIC ACID; COPPER INTRAUTERINE DEVICE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTATE; ESTROGEN; ESTRONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETONOGESTREL; INJECTABLE CONTRACEPTIVE AGENT; ISOTRETINOIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; ORTHO TRI-CYLEN; PLACEBO; PRASTERONE; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; TESTOSTERONE; UNCLASSIFIED DRUG; MINERALOCORTICOID ANTAGONIST;

ACNE VULGARIS; ANDROGEN SYNTHESIS; ANTIANDROGEN THERAPY; ARTICLE; BREAST CANCER; BREAST TENDERNESS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMEDO; CONTRACEPTIVE BEHAVIOR; CORONARY ARTERY DISEASE; DERMAL IMPLANT; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DYSKERATOSIS; DYSMENORRHEA; ESTROGEN SYNTHESIS; HORMONAL THERAPY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENSTRUAL IRREGULARITY; ORAL CONTRACEPTIVE USE; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; SEBACEOUS GLAND; SEBUM SECRETION; TRANSDERMAL PATCH; UTERINE CERVIX CANCER; VAGINA RING; VENOUS THROMBOEMBOLISM; CLINICAL COMPETENCE; PATIENT EDUCATION; PRACTICE GUIDELINE;

ACNE VULGARIS; CLINICAL COMPETENCE; CONTRACEPTIVES, ORAL, COMBINED; GUIDELINE ADHERENCE; HUMANS; ISOTRETINOIN; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PATIENT EDUCATION AS TOPIC; SPIRONOLACTONE;

EID: 84903955753     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2014.05.002     Document Type: Article

References (123)

1. Kurokawa I., Danby F.W., Ju Q., et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009, 18:821-832.
2. Zouboulis C.C. Acne and sebaceous gland function. Clin Dermatol 2004, 22:360-366.
3. Choudhry R., Hodgins M.B., Van der Kwast T.H., et al. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992, 133:467-475.
4. Liang T., Hoyer S., Yu R., et al. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol 1993, 100:663-666.
5. Imperato-McGinley J., Gautier T., Cai L.Q., et al. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993, 76:524-528.
6. Randall V.A., Ebling F.J. Is the metabolism of testosterone to 5 alpha-dihydrotestosterone required for androgen action in the skin?. Br J Dermatol 1982, 107(Suppl. 23):47-53.
7. Thiboutot D., Jabara S., McAllister J.M., et al. Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol 2003, 120:905-914.
8. Rosignoli C., Nicolas J.C., Jomard A., et al. Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo. Exp Dermatol 2003, 12:480-489.
9. Chen W., Yang C.C., Sheu H.M., et al. Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. J Invest Dermatol 2003, 121:441-447.
10. Thiboutot D., Gilliland K., Light J., et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol 1999, 135:1041-1045.
11. Akamatsu H., Zouboulis C.C., Orfanos C.E. Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands. J Invest Dermatol 1992, 99:509-511.
12. Thiboutot D.M., Knaggs H., Gilliland K., et al. Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 1997, 136:166-171.
13. Strauss J.S., Pochi P.E. Effect of cyclic progestin-estrogen therapy on sebum and acne in women. JAMA 1964, 190:815-819.
14. George R., Clarke S., Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg 2008, 27:188-196.
15. Kim G.K., Michaels B.B. Post-adolescent acne in women: more common and more clinical considerations. J Drugs Dermatol 2012, 11:708-713.
16. Williams C., Layton A.M. Persistent acne in women: Implications for the patient and for therapy. Am J Clin Dermatol 2006, 7:281-290.
17. Goulden V., Clark S.M., Cunliffe W.J. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997, 136:66-70.
18. Knaggs H.E., Wood E.J., Rizer R.L., et al. Post-adolescent acne. Int J Cosmet Sci 2004, 26:129-138.
19. Kim G.K., Del Rosso J.Q. Oral spironolactone in post-teenage female patients with acne vulgaris: Practical considerations for the clinician based on current data and clinical experience. J Clin Aesthet Dermatol 2012, 5:37-50.
20. Thiboutot D., Chen W. Update and future of hormonal therapy in acne. Dermatology 2003, 206:57-67.
21. Tremblay M.R., Luu-The V., Leblanc G., et al. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities. Bioorg Med Chem 1999, 7:1013-1023.
22. Armanini D., Karbowiak I., Goi A., et al. In-vivo metabolites of spironolactone and potassium canrenoate: Determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol (Oxf) 1985, 23:341-347.
23. Farquhar C., Lee O., Toomath R., et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2003, CD000194.
24. Archer J.S., Chang R.J. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004, 18:737-754.
25. Zouboulis C.C., Akamatsu H., Stephanek K., et al. Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone. Skin Pharmacol 1994, 7:33-40.
26. Brown J., Farquhar C., Lee O., et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2009, CD000194.
27. Walton S., Cunliffe W.J., Lookingbill P., et al. Lack of effect of topical spironolactone on sebum excretion. Br J Dermatol 1986, 114:261-264.
28. Muhlemann M.F., Carter G.D., Cream J.J., et al. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol 1986, 115:227-232.
29. Goodfellow A., Alaghband-Zadeh J., Carter G., et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 1984, 111:209-214.
30. Saint-Jean M., Ballanger F., Nguyen J.M., et al. Importance of spironolactone in the treatment of acne in adult women. J Eur Acad Dermatol Venereol 2011, 25:1480-1481.
31. Katsambas A.D., Dessinioti C. Hormonal therapy for acne: why not as first line therapy? facts and controversies. Clin Dermatol 2010, 28:17-23.
32. Hecker A., Hasan S.H., Neumann F. Disturbances in sexual differentiation of rat foetuses following spironolactone treatment. Acta Endocrinol (Copenh) 1980, 95:540-545.
33. Groves T.D., Corenblum B. Spironolactone therapy during human pregnancy. Am J Obstet Gynecol 1995, 172:1655-1656.
34. Krunic A., Ciurea A., Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol 2008, 58:60-62.
35. Rabe T., Kowald A., Ortmann J., et al. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000, 14:223-230.
36. Bitzer J., Tschudin S., Alder J. Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care 2004, 9:278-284.
37. Arowojolu A.O., Gallo M.F., Lopez L.M., et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2009, CD004425.
38. Lucky A.W., Henderson T.A., Olson W.H., et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997, 37:746-754.
39. Redmond G.P., Olson W.H., Lippman J.S., et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997, 89:615-622.
40. Estrostep [package insert] 2009, Warner Chilcott, Rockaway, NY.
41. Thorneycroft I.H. Evolution of progestins. Focus on the novel progestin drospirenone. J Reprod Med 2002, 47:975-980.
42. Koltun W., Lucky A.W., Thiboutot D., et al. Efficacy and safety of 3mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008, 77:249-256.
43. Fenton C., Wellington K., Moen M.D., et al. Drospirenone/ethinylestradiol 3mg/20microg (24/4day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs 2007, 67:1749-1765.
44. Maloney J.M., Dietze P., Watson D., et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008, 112:773-781.
45. U S. medical eligibility criteria for contraceptive use. MMWR Recomm Rep 2010, 59:1-86.
46. Beral V., Hermon C., Kay C., et al. Mortality associated with oral contraceptive use: 25year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999, 318:96-100.
47. Batur P., Elder J., Mayer M. Update on contraception: Benefits and risks of the new formulations. Cleve Clin J Med 2003, 70:681-690.
48. Chasan-Taber L., Stampfer M.J. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998, 128:467-477.
49. Martinez F., Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care 2007, 12:97-106.
50. Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol 2012, 24:235-240.
51. Tchaikovski S., Tans G., Rosing J. Venous thrombosis and oral contraceptives: current status. Women Health 2006, 2:761-772.
52. Heinemann L.A., Dinger J.C. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007, 75:328-336.
53. Heit J.A., Kobbervig C.E., James A.H., et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study. Ann Intern Med 2005, 143:697-706.
54. Pomp E.R., Lenselink A.M., Rosendaal F.R., et al. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008, 6:632-637.
55. Reid R. SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: An update. J Obstet Gynaecol Can 2010, 32:1192-1204.
56. Lidegaard O., Milsom I., Geirsson R.T., et al. Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand 2012, 91:769-778.
57. Spitzer W.O., Lewis M.A., Heinemann L.A., et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996, 312:83-88.
58. FDA Drug Safety Communication: Safety review update on the possible increased risk of blood clots with birth control pills containing drospirenone Available from:. http://www.fda.gov/Drugs/DrugSafety/ucm273021.htm.
59. La Vecchia C., Franceschi S. Third generation oral contraceptives and vascular risks. Eur J Public Health 2002, 12:81-82.
60. Family planning 2011: Better use of existing methods, new strategies and more informed choices for female contraception. Hum Reprod Update 2012, 18:670-681.
61. Wiegratz I., Thaler C.J. Hormonal contraception-what kind, when, and for whom?. Dtsch Arztebl Int 2011, 108:495-505.
62. Cibula D., Gompel A., Mueck A.O., et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010, 16:631-650.
63. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996, 347:1713-1727.
64. Marchbanks P.A., McDonald J.A., Wilson H.G., et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002, 346:2025-2032.
65. Drife J.O. The contraceptive pill and breast cancer in young women. BMJ 1989, 298:1269-1270.
66. Appleby P., Beral V., Berrington de Gonzalez A., et al. Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007, 370:1609-1621.
67. Sasieni P. Cervical cancer prevention and hormonal contraception. Lancet 2007, 370:1591-1592.
68. Harper J.C. Should dermatologists prescribe hormonal contraceptives for acne?. Dermatol Ther 2009, 22:452-457.
69. Lara-Torre E., Schroeder B. Adolescent compliance and side effects with Quick Start initiation of oral contraceptive pills. Contraception 2002, 66:81-85.
70. Westhoff C., Kerns J., Morroni C., et al. Quick start: Novel oral contraceptive initiation method. Contraception 2002, 66:141-145.
71. Westhoff C., Morroni C., Kerns J., et al. Bleeding patterns after immediate vs. conventional oral contraceptive initiation: A randomized, controlled trial. Fertil Steril 2003, 79:322-329.
72. Westhoff C., Heartwell S., Edwards S., et al. Initiation of oral contraceptives using a quick start compared with a conventional start: A randomized controlled trial. Obstet Gynecol 2007, 109:1270-1276.
73. Trussell J. Contraceptive failure in the United States. Contraception 2011, 83:397-404.
74. Gallo M.F., Lopez L.M., Grimes D.A., et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2011, CD003987.
75. Stewart F.H., Harper C.C., Ellertson C.E., et al. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence. JAMA 2001, 285:2232-2239.
76. Westhoff C.L., Jones H.E., Guiahi M. Do new guidelines and technology make the routine pelvic examination obsolete?. J Womens Health 2011, 20:5-10.
77. Archer J.S., Archer D.F. Oral contraceptive efficacy and antibiotic interaction: A myth debunked. J Am Acad Dermatol 2002, 46:917-923.
78. Weaver K., Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception 1999, 59:71-78.
79. Helms S.E., Bredle D.L., Zajic J., et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 1997, 36:705-710.
80. London B.M., Lookingbill D.P. Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives. Arch Dermatol 1994, 130:392-393.
81. Summers A. Interaction of antibiotics and oral contraceptives. Emerg Nurse 2008, 16:20-21.
82. Verhaeghe J. Clinical practice: Contraception in adolescents. Eur J Pediatr 2012, 171:895-899.
83. U.S.Food and Drug Administration iPLEDGE Program Prescriber Contraception Counseling Guide 2005, USFDA, Bethesda, MD.
84. Ventura S.J., Abma J.C., Mosher W.D., et al. Estimated pregnancy rates for the United States, 1990-2005: An update. Natl Vital Stat Rep 2009, 58:1-14.
85. Eaton D.K., Kann L., Kinchen S., et al. Youth risk behavior surveillance-United States, 2011. MMWR Surveill Summ 2012, 61:1-162.
86. Trussell J. Contraceptive efficacy. Contraceptive Technology 2007, Ardent Media, New York, NY. 19th rev. ed. R.A. Hatcher (Ed.).
87. Winner B., Peipert J.F., Zhao Q., et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012, 366:1998-2007.
88. Audet M.C., Moreau M., Koltun W.D., et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: A randomized controlled trial. JAMA 2001, 285:2347-2354.
89. Archer D.F., Cullins V., Creasy G.W., et al. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception 2004, 69:189-195.
90. Oddsson K., Leifels-Fischer B., de Melo N.R., et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: A 1-year randomized trial. Contraception 2005, 71:176-182.
91. Ahrendt H.J., Nisand I., Bastianelli C., et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3mg of drospirenone. Contraception 2006, 74:451-457.
92. FDA approves update to label on birth control patch Available from:. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116842.htm.
93. Cole J.A., Norman H., Doherty M., et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007, 109:339-346.
94. Jick S., Kaye J.A., Li L., et al. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2007, 76:4-7.
95. Jick S.S., Jick H. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch. Contraception 2006, 74:290-292.
96. Jick S.S., Kaye J.A., Russmann S., et al. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006, 73:223-228.
97. Jick S.S., Hagberg K.W., Hernandez R.K., et al. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception 2010, 81:16-21.
98. Lidegaard O., Nielsen L.H., Skovlund C.W., et al. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012, 344:e2990.
99. Gilliam M., Holmquist S., Berlin A. Factors associated with willingness to use the contraceptive vaginal ring. Contraception 2007, 76:30-34.
100. Carey A.S., Chiappetta L., Tremont K., et al. The contraceptive vaginal ring: female adolescents' knowledge, attitudes and plans for use. Contraception 2007, 76:444-450.
101. Lopez L.M., Grimes D.A., Gallo M.F., et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2010, CD003552.
102. Whitaker A.K., Gilliam M. Contraceptive care for adolescents. Clin Obstet Gynecol 2008, 51:268-280.
103. Lloyd T., Rollings N., Andon M.B., et al. Determinants of bone density in young women: relationships among pubertal development, total body bone mass, and total body bone density in premenarchal females. J Clin Endocrinol Metab 1992, 75:383-387.
104. Cromer B.A., Stager M., Bonny A., et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 2004, 35:434-441.
105. Scholes D., LaCroix A.Z., Ichikawa L.E., et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005, 159:139-144.
106. Hubacher D., Grimes D.A. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002, 57:120-128.
107. Sivin I., Stern J., Diaz S., et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Am J Obstet Gynecol 1992, 166:1208-1213.
108. Vessey M.P., Lawless M., McPherson K., et al. Fertility after stopping use of intrauterine contraceptive device. BMJ 1983, 286:106.
109. Castellsague X., Diaz M., Vaccarella S., et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: A pooled analysis of 26 epidemiological studies. Lancet Oncol 2011, 12:1023-1031.
110. Benshushan A., Paltiel O., Rojansky N., et al. IUD use and the risk of endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2002, 105:166-169.
111. Orbo A., Arnes M., Hancke C., et al. Treatment results of endometrial hyperplasia after prospective D-score classification: A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008, 111:68-73.
112. ACOG Committee Opinion No.392 Intrauterine device and adolescents. Obstet Gynecol 2007, 110:1493-1495.
113. McNicholas C., Peipert J.F. Long-acting reversible contraception for adolescents. Curr Opin Obstet Gynecol 2012, 24:293-298.
114. Hatcher R.A. Contraceptive technology 2007, Ardent Media, New York, NY. 19th rev. ed.
115. Allen R.H., Bartz D., Grimes D.A., et al. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev 2009, CD007373.
116. Nilsson C.G., Haukkamaa M., Vierola H., et al. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol 1982, 17:529-536.
117. Alvarez F., Brache V., Fernandez E., et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril 1988, 49:768-773.
118. Trussell J., Lalla A.M., Doan Q.V., et al. Cost effectiveness of contraceptives in the United States. Contraception 2009, 79:5-14.
119. Peipert J.F., Zhao Q., Allsworth J.E., et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011, 117:1105-1113.
120. Mommers E., Blum G.F., Gent T.G., et al. Nexplanon, a radiopaque etonogestrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial. Am J Obstet Gynecol 2012, 207:e381-e386. [388].
121. Mestad R., Secura G., Allsworth J.E., et al. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception 2011, 84:493-498.
122. Funk S., Miller M.M., Mishell D.R., et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005, 71:319-326.
123. Darney P., Patel A., Rosen K., et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): Results from 11 international clinical trials. Fertil Steril 2009, 91:1646-1653.